AP NEWS

Hyperalgesia Pipeline Review, H2 2018 - Therapeutic Assessment of 5 Companies & Drug Profiles - ResearchAndMarkets.com

September 26, 2018

DUBLIN--(BUSINESS WIRE)--Sep 26, 2018--The “Hyperalgesia - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Hyperalgesia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hyperalgesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The Hyperalgesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Hyperalgesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Hyperalgesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Report Coverage Hyperalgesia - Overview Hyperalgesia - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Hyperalgesia - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Hyperalgesia - Companies Involved in Therapeutics Development Abide Therapeutics Inc Boehringer Ingelheim GmbH Cara Therapeutics Inc Charleston Laboratories Inc Novartis AG

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5ftm9r/hyperalgesia?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180926006080/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Analgesics

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/26/2018 05:54 PM/DISC: 09/26/2018 05:53 PM

http://www.businesswire.com/news/home/20180926006080/en

AP RADIO
Update hourly